DeepMed Research

University Health Network

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1999-01-01

Employees: 10K

Market Cap: -

Website: http://www.uhn.ca

Clinical Trials

VRx@Home: Study to Evaluate VR-therapy for PwD Living at Home

Not Applicable

Completed

Conditions: Dementia

First Posted Date: 2021-08-03

Last Posted Date: 2022-10-18

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 7

Registration Number: NCT04988360

Locations: 🇨🇦
Acclaim Health, Oakville, Ontario, Canada
🇨🇦
Circle of Care, Toronto, Ontario, Canada

Patient Reported Outcomes/Metrics Program Trial

Recruiting

Conditions: Metastatic Cancer
Palliative

First Posted Date: 2021-07-30

Last Posted Date: 2025-02-20

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 100

Registration Number: NCT04983199

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Dyspnea in Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorder

Not Applicable

Completed

Conditions: Hypermobility Syndrome
Hypermobile EDS (hEDS)

Interventions: Behavioral: Usual Care plus Inspiratory Muscle Training (IMT)

First Posted Date: 2021-07-22

Last Posted Date: 2025-04-02

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 34

Registration Number: NCT04972565

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

The Relationship Between Cannabis Use, Biomarkers, Tissue Cannabinoid Levels and Clinical Outcomes in Patients With OA

Recruiting

Conditions: Osteo Arthritis Knee

First Posted Date: 2021-07-21

Last Posted Date: 2022-11-14

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 1200

Registration Number: NCT04971629

Locations: 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada

Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study)

Not Applicable

Active, not recruiting

Conditions: COVID-19 Vaccination
SARS-CoV-2
Myocardial Injury
Myocarditis
Cardiac MRI

Interventions: Diagnostic Test: Cardiac PET/MRI
Diagnostic Test: Blood Biomarkers

First Posted Date: 2021-07-20

Last Posted Date: 2025-04-02

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 57

Registration Number: NCT04967807

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19

Phase 3

Conditions: Sars-CoV2
Covid19

Interventions: Drug: Peginterferon Lambda-1A
Other: Placebo

First Posted Date: 2021-07-19

Last Posted Date: 2022-04-05

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 763

Registration Number: NCT04967430

Locations: 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada

Using ctDNA to Determine Therapies for Lung Cancer

Phase 2

Recruiting

Conditions: Non Small Cell Lung Cancer
Complete Surgical Resection
Circulating Tumor DNA

Interventions: Drug: Nivolumab
Drug: Pemetrexed
Drug: Gemcitabine
Drug: Cisplatin
Drug: Carboplatin
Procedure: ctDNA blood test

First Posted Date: 2021-07-19

Last Posted Date: 2024-07-22

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 66

Registration Number: NCT04966663

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

ODYSSEE-vCHAT Pilot Trial for Heart Failure

Not Applicable

Completed

Conditions: Heart Failure

Interventions: Behavioral: ODYSSEE-vCHAT

First Posted Date: 2021-07-19

Last Posted Date: 2024-12-19

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 61

Registration Number: NCT04966104

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada
🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada

Cancer Rehab Program for Allogenic Bone and Marrow Transplant Patients - CaRE-4-alloBMT

Not Applicable

Completed

Conditions: Hematologic Cancer
Allogeneic Disease
Cancer Rehabilitation

Interventions: Behavioral: CaRE-4-alloBMT plus usual care group

First Posted Date: 2021-07-19

Last Posted Date: 2023-05-09

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 80

Registration Number: NCT04966156

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer

Phase 2

Active, not recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Diagnostic Test: cfDNA blood test
Drug: Nivolumab
Drug: Ipilimumab
Combination Product: Platinum-based Chemotherapy

First Posted Date: 2021-07-19

Last Posted Date: 2024-07-19

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 5

Registration Number: NCT04966676

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy